Legal & General Group’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Legal & General Group’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,198	Closed	-$1.84K	–	3616
2023 Q1	$1.84K	Hold	7,198	–	–	﹤0.01%	3354
2022 Q4	$8.53K	Hold	7,198	–	–	﹤0.01%	3292
2022 Q3	$15K	Buy	+7,198	New	+$12.2K	﹤0.01%	3277

Legal & General Group's PEAR Position: Q2 2023 in Review

Legal & General Group sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 7,198 shares — an estimated $1.84K sold.

Legal & General Group first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $15K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Legal & General Group reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Legal & General Group sold 7,198 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.84K.
Legal & General Group first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
Legal & General Group's Pear Therapeutics, Inc. Class A Common Stock position peaked at $15K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.